MOZ-TIF2 Repression of Nuclear Receptor-mediated Transcription Requires Multiple Domains in MOZ and in the CID Domain of TIF2

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2007 Aug 19

PMID 17697320

Citations 5

Authors

Hong Yin

Jonathan Glass

Kerry L Blanchard

Affiliations

Soon will be listed here.

Abstract

Background: Fusion of the MOZ and TIF2 genes by an inv (8) (p11q13) translocation has been identified in patients with acute mixed-lineage leukemia. Characterization of the molecular structure of the MOZ-TIF2 fusion protein suggested that the fusion protein would effect on nuclear receptor signaling.

Results: A series of deletions from the N-terminus of the MOZ-TIF2 fusion protein demonstrated that the MOZ portion is essential for nuclear localization of the fusion protein. Transient expression of MOZ-TIF2 dramatically decreased both basal and estradiol inducible reporter gene activity in an estrogen receptor element (ERE) driven luciferase reporter system and decreased androgen-inducible reporter gene activity in an androgen receptor element (ARE) luciferase reporter system. Deletions in the MOZ portion of the MOZ-TIF2 fusion protein reduced the suppression in the ER reporter system. Stable expression of MOZ-TIF2 inhibited retinoic acid (RA) inducible endogenous CD11b and C/EBPbeta gene response. The suppression of the reporter systems was released with either a CID domain deletion or with mutations of leucine-rich repeats in the TIF2 portion of MOZ-TIF2. The co-expression of TIF2, but not CBP, with MOZ-TIF2 partially restored the inhibition of the reporter systems. In addition, analysis of protein interactions demonstrated MOZ-TIF2 interaction with the C-terminus of CBP through both the MOZ and TIF2 portions of the fusion protein.

Conclusion: MOZ-TIF2 inhibited nuclear receptor-mediated gene response by aberrant recruitment of CBP and both the MOZ and TIF2 portions are required for this inhibition.

Citing Articles

p160 nuclear receptor coactivator family members and their role in rare fusion‑driven neoplasms (Review).

Segovia D, Safaric Tepes P Oncol Lett. 2024; 27(5):210.

PMID: 38572059 PMC: 10988192. DOI: 10.3892/ol.2024.14343.

Patient-derived xenografts and in vitro model show rationale for imatinib mesylate repurposing in HEY1-NCoA2-driven mesenchymal chondrosarcoma.

Safaric Tepes P, Segovia D, Jevtic S, Ramirez D, Lyons S, Sordella R Lab Invest. 2021; 102(9):1038-1049.

PMID: 34837064 DOI: 10.1038/s41374-021-00704-4.

ETV6-NCOA2 fusion induces T/myeloid mixed-phenotype leukemia through transformation of nonthymic hematopoietic progenitor cells.

Fishman H, Madiwale S, Geron I, Bari V, Van Loocke W, Kirschenbaum Y Blood. 2021; 139(3):399-412.

PMID: 34624096 PMC: 9906988. DOI: 10.1182/blood.2020010405.

The Role of Histone Acetyltransferases in Normal and Malignant Hematopoiesis.

Sun X, Man N, Tan Y, Nimer S, Wang L Front Oncol. 2015; 5:108.

PMID: 26075180 PMC: 4443728. DOI: 10.3389/fonc.2015.00108.

The MYSTerious MOZ, a histone acetyltransferase with a key role in haematopoiesis.

Perez-Campo F, Costa G, Lie-A-Ling M, Kouskoff V, Lacaud G Immunology. 2013; 139(2):161-5.

PMID: 23347099 PMC: 3647182. DOI: 10.1111/imm.12072.

References

Chen S, Dowhan D, Hosking B, Muscat G . The steroid receptor coactivator, GRIP-1, is necessary for MEF-2C-dependent gene expression and skeletal muscle differentiation. Genes Dev. 2000; 14(10):1209-28. PMC: 316616. View

Chaffanet M, Gressin L, Preudhomme C, Soenen-Cornu V, Birnbaum D, Pebusque M . MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chromosomes Cancer. 2000; 28(2):138-44. DOI: 10.1002/(sici)1098-2264(200006)28:2<138::aid-gcc2>3.0.co;2-2. View

Panagopoulos I, Isaksson M, Lindvall C, Bjorkholm M, Ahlgren T, Fioretos T . RT-PCR analysis of the MOZ-CBP and CBP-MOZ chimeric transcripts in acute myeloid leukemias with t(8;16)(p11;p13). Genes Chromosomes Cancer. 2000; 28(4):415-24. DOI: 10.1002/1098-2264(200008)28:4<415::aid-gcc7>3.0.co;2-i. View

Goodman R, Smolik S . CBP/p300 in cell growth, transformation, and development. Genes Dev. 2000; 14(13):1553-77. View

von Mikecz A, Zhang S, Montminy M, Tan E, Hemmerich P . CREB-binding protein (CBP)/p300 and RNA polymerase II colocalize in transcriptionally active domains in the nucleus. J Cell Biol. 2000; 150(1):265-73. PMC: 2185550. DOI: 10.1083/jcb.150.1.265. View

De Guzman R, Liu H, Dyson H, Wright P . Solution structure of the TAZ2 (CH3) domain of the transcriptional adaptor protein CBP. J Mol Biol. 2000; 303(2):243-53. DOI: 10.1006/jmbi.2000.4141. View

Huntly B, Shigematsu H, Deguchi K, Lee B, Mizuno S, Duclos N . MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 2004; 6(6):587-96. DOI: 10.1016/j.ccr.2004.10.015. View

Kindle K, Troke P, Collins H, Matsuda S, Bossi D, Bellodi C . MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function. Mol Cell Biol. 2005; 25(3):988-1002. PMC: 544007. DOI: 10.1128/MCB.25.3.988-1002.2005. View

Lee Y, Coonrod S, Kraus W, Jelinek M, Stallcup M . Regulation of coactivator complex assembly and function by protein arginine methylation and demethylimination. Proc Natl Acad Sci U S A. 2005; 102(10):3611-6. PMC: 553305. DOI: 10.1073/pnas.0407159102. View

10.

Thomas T, Corcoran L, Gugasyan R, Dixon M, Brodnicki T, Nutt S . Monocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cells. Genes Dev. 2006; 20(9):1175-86. PMC: 1472476. DOI: 10.1101/gad.1382606. View

11.

Katsumoto T, Aikawa Y, Iwama A, Ueda S, Ichikawa H, Ochiya T . MOZ is essential for maintenance of hematopoietic stem cells. Genes Dev. 2006; 20(10):1321-30. PMC: 1472906. DOI: 10.1101/gad.1393106. View

12.

Collins H, Kindle K, Matsuda S, Ryan C, Troke P, Kalkhoven E . MOZ-TIF2 alters cofactor recruitment and histone modification at the RARbeta2 promoter: differential effects of MOZ fusion proteins on CBP- and MOZ-dependent activators. J Biol Chem. 2006; 281(25):17124-17133. DOI: 10.1074/jbc.M602633200. View

13.

Cleutjens K, van der Korput H, van Eekelen C, van Rooij H, Faber P, Trapman J . An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol. 1997; 11(2):148-61. DOI: 10.1210/mend.11.2.9883. View

14.

Heery D, Kalkhoven E, Hoare S, Parker M . A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997; 387(6634):733-6. DOI: 10.1038/42750. View

15.

Avantaggiati M, Ogryzko V, Gardner K, Giordano A, Levine A, Kelly K . Recruitment of p300/CBP in p53-dependent signal pathways. Cell. 1997; 89(7):1175-84. DOI: 10.1016/s0092-8674(00)80304-9. View

16.

Goldman P, Tran V, Goodman R . The multifunctional role of the co-activator CBP in transcriptional regulation. Recent Prog Horm Res. 1997; 52:103-19; discussion 119-20. View

17.

Voegel J, Heine M, Tini M, Vivat V, Chambon P, Gronemeyer H . The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J. 1998; 17(2):507-19. PMC: 1170401. DOI: 10.1093/emboj/17.2.507. View

18.

Ding X, Anderson C, Ma H, Hong H, Uht R, Kushner P . Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. Mol Endocrinol. 1998; 12(2):302-13. DOI: 10.1210/mend.12.2.0065. View

19.

Carapeti M, Aguiar R, Goldman J, Cross N . A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood. 1998; 91(9):3127-33. View

20.

Dayton M, Knobloch T . Multiple phosphotyrosine phosphatase mRNAs are expressed in the human lung fibroblast cell line WI-38. Recept Signal Transduct. 1997; 7(4):241-56. View